ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

exagamglogene autotemcel

Also written as “CTX001”, “Exa-cel” and “CTX001 With and Without Iron”.

Its studies are mostly in beta-Thalassemia · Anemia, Sickle Cell · Renal Insufficiency, Chronic · Anemia, led by 2 companies.

Drug pageExagamglogene autotemcel: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 29, 20189 company-led studies, 6 open or runningNext primary completion: Jun 6, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticalsits history only74 open or runningphase 3since Aug 29, 2018Aug 29, 2018Jun 6, 2027phase 3 · NCT05329649
Cajal Therapeutics22 open or runningphase 1since Oct 22, 2026May 5, 2026Oct 2027phase 1 · NCT07901933

Also a collaborator on its studies: CRISPR Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cajal Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named exagamglogene autotemcelINNProposed as its International Nonproprietary Name in WHO's List 124 · before, CTX001
  2. May 5, 2026First study: early phase 1 study in AnemiaFirst studyNCT07577817 · 72 planned · Australia
  3. Oct 22, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07901933 · 24 planned · Australia

Ahead

  1. Oct 2027Primary completion: phase 1 study in Renal Insufficiency, ChronicNCT07901933

TargetBeta

BCL11A →read by rule
“B-cell lymphoma/leukemia 11A gene editing negative modulator”ChEMBL 37, by rule

Studies

All 2 Cajal Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07901933Renal Insufficiency, Chronic · Australia1Not yet recruitingOct 202724
NCT07577817Anemia · AustraliaEarly 1RecruitingOct 202672

How it is read

Names in the registry

  • “CTX001”, 6 entries
  • “Exa-cel”, 2 entries
  • “CTX001 With and Without Iron”, 1 entry
  • “CTX001 With Iron”, 1 entry
  • “CTX001 Multiple Dose”, 1 entry

Codes read as this program: CTX001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.